research peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
=== Diversification and decline === The ensuing financial crisis prompted a major strategic transition. In 1970, HVEC's losses represented 31 percent of total stockholder investment. The company laid off 100 employees and suspended many research programs, citing insufficient federal funding for basic physics research. That year also marked a leadership transition: Pascal Levesque, head of the profitable HVEC subsidiary Electronized Chemicals Corporation, became president and chief executive, while departing president Denis Robinson assumed the chairmanship held by Trump. Under new management, HVEC diversified into industrial applications of its accelerator technologies. By 1972, the company had reorganized as a miniconglomerate with more than ten subsidiaries manufacturing plastics, power equipment, and radiation processing systems—products enabled by particle accelerators rather than particle accelerators themselves. The diversification strategy yielded several commercially successful products. Electronized Chemicals Corporation's heat-shrink tubing, made by electron-beam crosslinking of polyethylene, became ubiquitous in electrical wiring. The technology enabled modern wire harnesses in automobiles and aircraft, where compact, reliable insulation was essential. Ion Physics Corporation introduced radiation-based ion implantation, enabling precise control of transistor characteristics in integrated circuits. HVEC closed Ion Physics in 1971, but became standard practice throughout the global semiconductor industry by the late 1970s.
Thus, the two substrates of this enzyme are D-galactose (shown in its aldehydo form) and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are D-galactono-1,5-lactone, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is D-galactose:NADP+ 1-oxidoreductase. Other names in common use include D-galactose dehydrogenase (NADP+), and galactose 1-dehydrogenase (NADP+). This enzyme participates in galactose metabolism.
One interpretation of the data is that polypeptide monomers are often aligned in the multimer in such a way that mutant polypeptides defective at nearby sites in the genetic map tend to form a mixed multimer that functions poorly, whereas mutant polypeptides defective at distant sites tend to form a mixed multimer that functions more effectively. Direct interaction of two nascent proteins emerging from nearby ribosomes appears to be a general mechanism for homo-oligomer (multimer) formation. Hundreds of protein oligomers were identified that assemble in human cells by such an interaction. The most prevalent form of interaction is between the N-terminal regions of the interacting proteins. Dimer formation appears to be able to occur independently of dedicated assembly machines. The intermolecular forces likely responsible for self-recognition and multimer formation were discussed by Jehle.
One for the transfer of unfolded chains from water to the bilayer interface (referred to as the Wimley–White interfacial hydrophobicity scale). One for the transfer of unfolded chains into octanol, which is relevant to the hydrocarbon core of a bilayer. The website of Stephen H. White provides an example of whole residue hydrophobicity scales showing the free energy of transfer ΔG(kcal/mol) from water to POPC interface and to n-octanol. These two scales are then used together to make Whole residue hydropathy plots. The hydropathy plot constructed using ΔGwoct − ΔGwif shows favorable peaks on the absolute scale that correspond to the known TM helices. Thus, the whole residue hydropathy plots illustrate why transmembrane segments prefer a transmembrane location rather than a surface one.
=== Dietary sources === Tryptophan is present in most protein-based foods or dietary proteins. It is particularly plentiful in chocolate, oats, dried dates, milk, yogurt, cottage cheese, red meat, eggs, fish, poultry, sesame, legumes such as chickpeas and soybeans, almonds, sunflower seeds, pumpkin seeds, hemp seeds, buckwheat, spirulina, and peanuts. Contrary to the popular belief that cooked turkey contains an abundance of tryptophan, the tryptophan content in turkey is typical of poultry.
Sources: en.wikipedia.org
== History == Wallerian degeneration is named after Augustus Volney Waller. Waller experimented on frogs in 1850, by severing their glossopharyngeal and hypoglossal nerves. He then observed the distal nerves from the site of injury, which were separated from their cell bodies in the brain stem. Waller described the disintegration of myelin, which he referred to as "medulla", into separate particles of various sizes. The degenerating axons formed droplets that could be stained, thus allowing for studies of the course of individual nerve fibres.
Selenols (R−SeH) are the selenium equivalents of alcohols and thiols. relatively unstable and generally have an unpleasant smell. Benzeneselenol (also called selenophenol or PhSeH) is more acidic (pKa 5.9) than thiophenol (pKa 6.5) and also oxidizes more readily to the diselenide. Indeed, selenophenol is prepared by reduction of diphenyldiselenide as the former is not air-stable. Diselenides (R−Se−Se−R) are the selenium equivalents of peroxides and disulfides. They are useful shelf-stable precursors to more reactive organoselenium reagents such as selenols and selanyl halides. Diselenides are typically prepared from the autoxidation of selenolates or alkylation of the diselenide anion, but secondary diselenides can be produced from the hydrogen selenide reduction of ketones. Best known in organic chemistry is diphenyldiselenide, prepared from phenylmagnesium bromide and selenium followed by aerobic oxidation of the product PhSeMgBr. Heating decomposes them to selenoethers or (in rare cases) the coupled alkane. Selanyl halides (R−Se−Cl, R−Se−Br) are prepared by halogenation of diselenides. For example, bromination of diphenyldiselenide gives phenylselanyl bromide (PhSeBr). These compounds are Lewis acidic, often stabilized by intramolecular coordination, and sources of "PhSe+". Excess halogen gives the corresponding trihalides. Selenides (R−Se−R), also called selenoethers, are the selenium equivalents of ethers and sulfides. One example is dimethylselenide ((CH3)2Se). These are the most prevalent organoselenium compounds.
=== Permethrin === Permethrin, a pyrethroid insecticide, is the most effective treatment for scabies, and remains the treatment of choice. It is applied from the neck down, usually before sleep, and left on for about 8 to 14 hours, then washed off in the morning. Care should be taken to coat the entire skin surface, not just symptomatic areas; any patch of skin left untreated can provide a "safe haven" for one or more mites to survive. One application is normally sufficient, as permethrin kills eggs, hatchlings, and adult mites, though many physicians recommend a second application three to seven days later as a precaution. Crusted scabies may require multiple applications or supplemental treatment with oral ivermectin (below). Permethrin may cause slight irritation of the skin that is usually tolerable. In recent years, concern has grown regarding the development of permethrin-resistant scabies. 2022 studies performed in Kuşadası, Turkey showed in cases where patients failed to improve with 5% permethrin, 100% of scabies mites analyzed were sensitive to in-vitro 5% permethrin, suggesting that lack of efficacy could be due to treatment non-compliance rather than true resistance. However, a 2024 study published in Salzburg, Austria revealed permethrin resistant-scabies in nearly 3 out of 4 cases studied. In this population, treatment with benzyl benzoate had a considerably higher cure rate. Additional studies will be needed to confirm the presence of permethrin-resistance and to determine its epidemiology.
EPA – Radionuclides – EPA's Radiation Protection Program: Information. FDA – Radionuclides – FDA's Radiation Protection Program: Information. Interactive Chart of Nuclides – A chart of all nuclides National Isotope Development Center – U.S. Government source of radionuclides – production, research, development, distribution, and information The Live Chart of Nuclides – IAEA Radionuclides production simulator – IAEA
According to the 2022 Brazilian census, 45.3% of the population (92.1 million) described themselves as Pardo (meaning brown or multiracial), 43.5% (88.2 million) as White, 10.2% (20.7 million) as Black, 0.6% (1.2 million) as Indigenous and 0.4% (850,000) as East Asian (officially called yellow or amarela). Since the arrival of the Portuguese in 1500, considerable genetic mixing between Amerindians, Europeans, and Africans has taken place in all regions of the country:
Sources: en.wikipedia.org
=== Dietary === The effects of eating habits on childhood obesity are difficult to determine. A three-year randomized controlled study of 1,704 third-grade children which provided two healthy meals a day in combination with an exercise program and dietary counselling failed to show a significant reduction in percentage body fat when compared to a control group. This was partly due to the fact that even though the children believed they were eating less, their actual calorie consumption did not decrease with the intervention. At the same time observed energy expenditure remained similar between the groups. This occurred even though dietary fat intake decreased from 34% to 27%. A second study of 5,106 children showed similar results. Even though the children ate an improved diet there was no effect found on BMI. Why these studies did not bring about the desired effect of curbing childhood obesity has been attributed to the interventions being insufficient. Changes were made primarily in the school environment while it is felt that they must occur in the home, the community, and the school simultaneously to have a significant effect. A Cochrane review of a lower fat diet in children (30% or less of total energy) to prevent obesity found the existing evidence of very low to moderate quality, and firm conclusions could not be made. Calorie-rich drinks and foods are readily available to children. Consumption of sugar-laden soft drinks may contribute to childhood obesity.
== Epidemiology == ALD has not been shown to have an increased incidence in any specific country or ethnic group. In the United States, the incidence of affected males is estimated at 1:21,000. Overall incidence of hemizygous males and carrier females is estimated at 1:16,800. The reported incidence in France is estimated at 1:22,000.
== Patterns of amino acid replacement == Evolution of proteins is slower than DNA since only nonsynonymous mutations in DNA can result in amino acid replacements. Most mutations are neutral to maintain protein function and structure. Therefore, the more similar amino acids are, the more probable that they will be replaced. Conservative replacements are more common than radical replacements, since they can result in less important phenotypic changes. On the other hand, beneficial mutations, enhancing protein functions are most likely to be radical replacements. Also, the physicochemical distances, which are based on amino acids properties, are negatively correlated with probability of amino acids substitutions. Smaller distance between amino acids indicates that they are more likely to undergo replacement.
Due to competition, the early 1980s recession, the early 1990s recession, and lost focus, the company's growth stalled in the 1980s and early 1990s. D’Arbeloff, the chairman of the company, died of cancer and the COO and CTO died in a helicopter crash while commuting between facilities. The anticipated synergies never materialized. In 1994, an investor group led by management purchased the company for $360 million. That year, the company introduced Symmetry HPLC columns. It had a renewed focus for growth under CEO Douglas A. Berthiaume. Pharmaceutical spending also increased after the failure of the Clinton health care plan of 1993. In November 1995, the company once again became a public company via an initial public offering. In 1996, in addition to acquiring TA Instruments, it introduced the Alliance HPLC system. The following year, Waters acquired Micromass for $176 million, entering the mass spectrometry market. In 2004, the company introduced the Acquity UPLC system, which brought greater speed, resolution, and sensitivity to chromatographic separations and was considered a breakthrough technology. In 2006, Waters acquired Vicam, provider of bio-separation and rapid detection products for improving food safety and quality. In January 2020, it acquired Andrew Alliance, a producer of software and robotics for laboratory automation, for $77.4 million. In September, Udit Batra was named President and Chief Executive Officer of the company. In May 2023, Waters acquired Wyatt Technology for $1.36 billion in cash.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.